

Prostate Cancer Clinical Trial Discussion Guide

This guide can help you start a conversation with your doctor about enrolling in a clinical trial. The first step is to talk to your doctor about whether you are eligible to participate.

CONTACT•02 is a clinical trial studying a combination of drugs called cabozantinib and atezolizumab for a type of prostate cancer called metastatic castration-resistant prostate cancer (mCRPC). Both you and your doctor can find additional information about this trial on [ClinicalTrials.gov](https://www.clinicaltrials.gov) by searching for **NCT04446117**.

If your doctor is not participating in CONTACT•02 research, you may need to discuss some questions with a healthcare provider who is participating in this trial. For more information, call **1-888-393-5494** (toll-free) or **1-303-389-1847**.

1. Your cancer and prior medications

- CONTACT•02 is studying cabozantinib and atezolizumab for mCRPC. Is this the type of cancer I have?
- CONTACT•02 is only enrolling men who have previously received only one of the newer hormonal therapies (abiraterone, apalutamide, darolutamide, or enzalutamide). Can we review all the medications I have received so far and whether I am eligible for this trial?

2. Clinical trial participation

- What are the potential risks and benefits if I participate?
- Is there anything you feel I should know about clinical trial participation?
- Can you help me get in touch with a doctor who is running this trial in my area?

3. Financial costs

- Who can I talk to in order to understand the cost related to the trial and what my health insurance covers?
- How can I find out more information?

The CONTACT clinical program is a collaboration between Exelixis and Roche-Genentech to evaluate cabozantinib in combination with atezolizumab in multiple solid tumors. CONTACT•02 is sponsored by Exelixis.

**THE USE OF CABOZANTINIB AND ATEZOLIZUMAB DESCRIBED HERE IS INVESTIGATIONAL.
SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.**